TRIUMPH Phase 3 Results: Retatrutide Efficacy Data Across Obesity & Comorbidities

Glycemic Control

Beyond weight reduction, retatrutide substantially improved glycemic control. Participants treated with the 9 mg and 12 mg doses achieved average HbA₁c reductions of 1.6% and 1.5%, respectively, while the 4 mg group reduced HbA₁c by 1.4%. Notably, up to 40% of trial participants receiving retatrutide 12 mg achieved an HbA₁c <5.7%, considered normoglycemic in clinical research contexts.

TRIUMPH-1: Retatrutide in Adults with Obesity Without Diabetes

A companion Phase 3 trial evaluated retatrutide in 2,339 adults with obesity (BMI ≥30 kg/m²) but without type 2 diabetes. This trial included nested protocols for participants with knee osteoarthritis (n=574) and obstructive sleep apnea (n=243).

Weight Loss in Non-Diabetic Obesity

The mean percentage changes in bodyweight were notably larger in this population:

• Retatrutide 4 mg: −17.6%
• Retatrutide 9 mg: −23.7%
• Retatrutide 12 mg: −25.0%
• Placebo: −3.9%

These results indicate that the absence of concurrent type 2 diabetes may be associated with greater weight-loss responsiveness to retatrutide in this trial population, though direct comparison requires careful consideration of baseline characteristics and study design differences.

TRIUMPH-3: Retatrutide in Adults with Severe Obesity and Cardiovascular Disease

TRIUMPH-3 enrolled 1,949 participants with severe obesity (BMI ≥35 kg/m²) and established cardiovascular disease, randomized to retatrutide 9 mg, 12 mg, or placebo. At baseline, the mean bodyweight was 111.4 kg with a BMI of 40.4 kg/m².

Weight Loss in Cardiovascular Disease Population

At 80 weeks, the primary efficacy endpoint showed:

• Retatrutide 9 mg: −21.6% (approximately −23.9 kg)
• Retatrutide 12 mg: −22.6% (approximately −25.3 kg)
• Placebo: −3.2% (approximately −3.5 kg)

Cardiovascular Risk Factor Reduction

Retatrutide produced substantial reductions in multiple cardiovascular risk factors. With the 12 mg dose, trial participants achieved:

• Triglycerides: −37.0% to −39.5%
• Non-HDL cholesterol: −16.5% to −19.6%
• Systolic blood pressure: −9.3 to −10.8 mmHg
• Waist circumference: approximately −16.9 to −19.0 cm
• High-sensitivity C-reactive protein (hsCRP): −51.2% to −58.3%

Notably, major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms, limiting the ability to detect between-group differences in this endpoint.

Safety Profile and Adverse Events

Across all TRIUMPH trials, the most frequently reported adverse events were gastrointestinal in nature. In TRIUMPH-2:

• Diarrhea: 27% (4 mg), 34% (9 mg), 34% (12 mg) vs. 13% (placebo)
• Nausea: 14% (4 mg), 21% (9 mg), 28% (12 mg) vs. 8% (placebo)

Other adverse events more common with retatrutide included:

• Hypotension: 1% (4 mg), 5% (9 mg), 6% (12 mg) vs. <1% (placebo)
• Dysesthesia: 4% (4 mg), 6% (9 mg), 7% (12 mg) vs. 1% (placebo)

Treatment Discontinuation

Permanent treatment discontinuation due to adverse events was dose-dependent. In TRIUMPH-2, discontinuation rates were 4% (4 mg), 12% (9 mg), 8% (12 mg), and 5% (placebo). Of 1,152 randomized participants, 84% completed the study drug.

Mortality was low across all groups: two deaths in the 4 mg group, three in the 9 mg group, one in the 12 mg group, and one in placebo. All deaths were deemed unrelated to the study intervention by investigators.

Mechanistic Considerations and Clinical Implications

The triple agonist mechanism of retatrutide—activating GIP, GLP-1, and glucagon receptors—distinguishes it from dual GLP-1/GIP agonists and single GLP-1 receptor agonists. The dose-dependent weight loss and metabolic improvements observed across TRIUMPH trials suggest that activation of all three pathways contributes to the drug's efficacy profile.

The substantial reductions in cardiovascular risk factors—particularly triglycerides and hsCRP—observed in TRIUMPH-3 align with emerging understanding of how weight loss and improved metabolic parameters influence systemic inflammation and lipid metabolism. However, the lower-than-anticipated MACE event rate in both treatment and placebo arms limits definitive conclusions regarding cardiovascular outcomes in this trial.

Gastrointestinal Tolerability and Dose Selection

The higher incidence of gastrointestinal adverse events at higher doses, coupled with increased discontinuation rates, suggests that individual tolerability may influence dose selection in clinical practice. The 4 mg dose demonstrated a more favorable discontinuation profile (4% vs. 5% placebo) while still producing clinically meaningful weight loss (11.9% in TRIUMPH-2, 17.6% in TRIUMPH-1).

Research and Regulatory Context

These Phase 3 results represent the most comprehensive clinical evaluation of a triple GLP-1/GIP/glucagon receptor agonist to date. The basket-trial design, encompassing obesity with and without comorbidities, provides robust evidence for retatrutide's efficacy across diverse patient populations. Researchers seeking information on eli lilly retatrutide phase iii results or retatrutide efficacy data will find these trials represent the current standard for evaluating triple agonist efficacy in obesity and metabolic disease.

Future Research Directions

Outstanding questions for future investigation include long-term durability of weight loss after treatment discontinuation, comparative efficacy against other GLP-1 receptor agonists and dual GIP/GLP-1 agonists, and identification of biomarkers predicting individual responsiveness to retatrutide. Additionally, mechanistic studies exploring the relative contributions of GIP, GLP-1, and glucagon receptor activation to weight loss and metabolic improvements may inform rational design of future obesity therapeutics.

Conclusion

The TRIUMPH Phase 3 trial program demonstrates that retatrutide produces substantial, dose-dependent weight loss and improvements in glycemic control and cardiovascular risk factors across diverse populations with obesity, with or without type 2 diabetes and cardiovascular comorbidities. The safety profile, characterized primarily by gastrointestinal adverse events, aligns with known effects of GLP-1 receptor agonism. These results support retatrutide as a potential therapeutic option for obesity and obesity-related metabolic disease, pending regulatory review and approval.

Key Takeaways

1. Retatrutide produced dose-dependent weight reductions ranging from 11.9% to 25.0% across TRIUMPH trials, compared to 3.2–5.1% with placebo over 80 weeks.
2. Glycemic control improved significantly in trial participants with type 2 diabetes, with up to 40% achieving normoglycemic A1C levels (<5.7%) in TRIUMPH-2.
3. Cardiovascular risk factors—including triglycerides (−37% to −39.5%), non-HDL cholesterol (−16.5% to −19.6%), and high-sensitivity C-reactive protein (−51.2% to −58.3%)—were substantially reduced in TRIUMPH-3.
4. Gastrointestinal adverse events (nausea, diarrhea) were the most common safety signals, with higher discontinuation rates observed at higher doses (8–12% vs. 4–5% placebo).